Esperion Therapeutics, INC 10-Q quarterly reports

Esperion Therapeutics reports Q1 2026 financial results while detailing a pending merger agreement and the recent acquisition of Corstasis Therapeutics.

Esperion Therapeutics reported an increased net loss for Q3 and the first nine months of 2025, despite growth in product sales and collaboration revenue, driven by higher operating and interest expenses.

Esperion Therapeutics reports a net loss of $12.7 million for Q2 2025, an improvement from the prior year, driven by robust product sales and new international collaborations, despite increased interest expenses and a material weakness in internal controls.

Esperion Therapeutics' Q1 2025 shows increased product sales but a decrease in collaboration revenue compared to Q1 2024, resulting in a net loss.

Esperion Therapeutics saw a significant increase in revenue for the third quarter of 2024, driven by both product sales and collaboration agreements.

Esperion Therapeutics saw a significant boost in revenue in the second quarter of 2024, primarily due to a settlement agreement and increased product sales, while also achieving expanded labels for its key products.

Esperion Therapeutics experienced a significant financial turnaround in Q1 2024, driven by a $100 million settlement payment and increased product sales.